Skip to content

Clinical efficacy of IORT on patients with unrectable pancreatic body-tail carcinoma: a randomized controlled trial

Clinical efficacy of IORT on patients with unrectable pancreatic body-tail carcinoma: a randomized controlled trial

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-TRC-11001470
Enrollment
Unknown
Registered
2011-07-28
Start date
2011-09-01
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

pancreatic body-tail carcinoma

Interventions

Unresectable pancreatic cancer in operation:IORT
Unresectable pancreatic cancer in operation:natural light

Sponsors

Ruijin Hospital affiliated to Shanghai JiaoTong University school of medicine
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Male and female aged 18 to 70 years old; Patients who are clinically diagnosed as pancreatic body-tail carcinoma have good body situation and basic normal nutrition condition. They haven't undergone any preoperative chemotherapy or radiotherapy. They haven't severe dysfunction of heart,l ung, liver and kidney, and no Jaundice, ascites, obstructive alimentary tract and acute infection. The routine blood test is normal with WBC>=4,000/mm3, Hb>=100g/L and plt>=100,000/mm3. The coagulation parameters are normal with PT, KPTT and TT in normal range. Quality of life grading (Karnofsky criteria) is over 80 scores. Operative endurance is good to endure operation and chemo-radiotherapy; 2. Patients are able and willing to provide signed informed consent; 3. Unresectable pancreatic cancer in operation.

Exclusion criteria

Exclusion criteria: 1. Patients with uncontrolled heart failure, infection, mental illness, dysfunction of heart, lung, liver or kidney; Patients who have undergone any preoperative chemotherapy or radiotherapy; and patients who wouldn’t receive operation or chemo-radiotherapy; 2. Pregnant or lactating women; 3. Patients who refused to sign agreement or receive therapy and following-up according to our research approach; 4. Patients who are diagnosed as non-pancreatic carcinoma by the postoperative pathological examination; 5. Life expectancy less than 6 months

Design outcomes

Primary

MeasureTime frame
Safety Assessment;Quality of life scores;disease free survival time;Postoperative survival time;

Secondary

MeasureTime frame
Safety Assessment;

Countries

China

Contacts

Public ContactBai-yong SHEN
shenbaiyong@medmail.com.cn+86 13901943778

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026